KA/EN
Register
Medicines reference
Search
Search
Active substance

Dexpanthenol

Favourites

Provitamin B5. Registered in Georgia: 1 veterinary product and 1 human medicine. Forms: cream, gel.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Dexpanthenol
Georgian name
დექსპანთენოლი
Authorisation status
Complementary feed / supplement
Not a medicine and not required to be authorised as one - it is sold under feed law.
Registered in Georgia
2 of 3 forms
Products
Bepanthen Plus, Glumax, Ivermek Gel
Human medicines in Georgia
Bepanthen, Pantenol, Panthenol aerosol, Recreol, Spenten
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration3

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Bepanthen Plus, Cream

dexpanthenol 50 mg/g + chlorhexidine dihydrochloride 5 mg/g, cream 30 g, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Adjunctive topical care of a cleaned small superficial skin wound or abrasion with credible infection risk, after exclusion or separate management of deep injury, established infection and wounds requiring debridement, drainage or closure
5.0/10
Weak evidence support
vetman assessment

Bepanthen Plus

dexpanthenol 50 mg/g + chlorhexidine dihydrochloride 5 mg/g, cream 30 g, human medicine
Assessed clinical scopeDog · Adjunctive topical care of a cleaned small superficial skin wound or abrasion with credible infection risk, after exclusion or separate management of deep injury, established infection and wounds requiring debridement, drainage or closure · On the skin
Care settingVeterinarian-directed outpatient or inpatient use on a small accessible lesion with planned licking prevention, wound monitoring and escalation if healing or infection control is inadequate
vetman score 5.0/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-038463 · Verified on 22 Oct 2026 Off-label use

A weak, narrowly situational off-label option for a cleaned small superficial canine wound at infection risk. Chlorhexidine class evidence and exact human transparency support plausibility, but no exact-cream canine outcome or damaged-skin safety study justifies a stronger claim.

Regulatory and scientific credibility6.0/10

The exact 30 g human cream has transparent composition, current Georgian and EU human authorisations and current official labels; canine chlorhexidine guidance and studies provide a scientific bridge. It has no veterinary authorisation or exact-product dog dossier, and salt, concentration, vehicle and clinical-scope transfer is substantial.

Clinical efficacy4.0/10

Canine chlorhexidine data support topical antisepsis, including 0.5% healthy-skin and 0.05% wound-lavage evidence, while human dexpanthenol evidence supports a healing rationale. No canine trial tested exact Bepanthen Plus, dihydrochloride cream or the fixed combination; formulation-mismatched evidence caps efficacy at 4/10.

Safety and tolerability4.5/10

Exact human risks and excipients are transparent, and 14-day 0.5% chlorhexidine gluconate exposure did not disrupt measured barrier function in six healthy dogs. Open/damaged skin, dihydrochloride cream, licking, lanolin/contact allergy and repeated-use tolerance remain untested; chlorhexidine is dangerous to the cornea.

Clinical practicality6.0/10

The ready 30 g leave-on cream is simple to target to a small cleaned lesion and can be covered, with no preparation or mg/kg calculation. Reliable licking prevention, site exclusions, dressing surveillance and the absence of a validated veterinary amount/frequency add meaningful but manageable burden.

Full-course cost-effectiveness-

A current 30 g Georgian tube price was verified, but lesion-area-adjusted total course use, dressing needs, wastage and comparable veterinary alternatives were not; price is excluded from the denominator.

Important safety and use flags

  • This score covers only adjunctive care of a cleaned small superficial skin wound with credible infection risk. It does not cover deep, puncture/bite, devitalised, heavily contaminated, abscessed, large-area or established infected wounds, pyoderma generally, surgical closure or burns requiring specialist care.
  • Bepanthen Plus is a human medicine and dog/cat use is off-label. No exact-product veterinary amount, frequency or course is established; do not copy the human up-to-four-times-daily label or another chlorhexidine product’s regimen.
  • Examine and clean the wound first. Deep pockets, devitalised tissue, foreign material, bite/puncture injury, exudate, spreading inflammation, fever, pain or poor healing requires drainage, debridement, culture, closure or systemic treatment as clinically indicated.
  • Keep away from eyes and periocular skin, mucosa and the ear canal when tympanic integrity is unknown. Chlorhexidine can cause severe corneal damage; ocular exposure requires immediate copious irrigation and urgent assessment if signs persist.
  • Prevent licking and ingestion until the site is protected or the cream is no longer accessible. Use a collar or secure nonconstrictive dressing when needed, and inspect for maceration, pressure, swelling, discharge or impaired circulation.
  • Stop immediately for increasing erythema, pruritus, pain, swelling, urticaria, facial swelling, breathing difficulty or another local/systemic hypersensitivity sign. Chlorhexidine can rarely cause anaphylaxis; lanolin, cetyl alcohol and stearyl alcohol can cause contact dermatitis.
  • Do not apply over a large area or continue frequent repeated use without review. Exact damaged-skin absorption and repeated-use tolerance are unknown, and canine cell data show concentration-dependent chlorhexidine cytotoxicity even when short healthy-skin exposure appears acceptable.
  • Do not combine on the same site with soaps/anionic compounds or another topical antiseptic without compatibility review. Organic debris can reduce topical antiseptic performance; cleaning and direct lesion contact matter.
  • Do not use antibacterial cream where infection risk is not credible merely to promote healing. Avoid unnecessary antiseptic exposure and choose a non-antiseptic wound/barrier product when that better matches the diagnosed lesion.
  • Safety in pregnant, lactating, breeding or juvenile dogs and cats is not established for repeated use on damaged skin. Make an explicit patient-specific benefit-risk decision and prevent neonate or littermate contact/ingestion.
Assessment sources
  1. Bepanthen Plus GE register2026
  2. Bepanthen Plus Lithuania register2026
  3. Bepanthen Plus HALMED leaflet2024
  4. Bepanthen Plus Aversi 30 g2026
  5. Malaseb dog/cat SPC2025
  6. ISCAID canine pyoderma guideline2025
  7. Canine daily chlorhexidine skin study2025
  8. Canine chlorhexidine wound study1992
  9. Canine antiseptic wound study2024
  10. Mixed-pet dexpanthenol ointment study2023
  11. Topical dexpanthenol review2002
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Adjunctive topical care of a cleaned small superficial skin wound or abrasion with credible infection risk, after exclusion or separate management of deep injury, established infection and wounds requiring debridement, drainage or closure
4.2/10
Weak evidence support
vetman assessment

Bepanthen Plus

dexpanthenol 50 mg/g + chlorhexidine dihydrochloride 5 mg/g, cream 30 g, human medicine
Assessed clinical scopeCat · Adjunctive topical care of a cleaned small superficial skin wound or abrasion with credible infection risk, after exclusion or separate management of deep injury, established infection and wounds requiring debridement, drainage or closure · On the skin
Care settingVeterinarian-directed outpatient or inpatient use on a small accessible lesion with planned licking prevention, wound monitoring and escalation if healing or infection control is inadequate
vetman score 4.2/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-038463 · Verified on 22 Oct 2026 Off-label use

A weak off-label option with greater uncertainty in cats. A different rinse-off feline chlorhexidine product and mixed-species dexpanthenol data do not resolve leave-on efficacy, grooming ingestion or exact-product tolerance; use only when exposure can be controlled and better-supported care is not displaced.

Regulatory and scientific credibility5.5/10

The exact 30 g human cream has transparent composition and current Georgian/EU human authorisation, and a different chlorhexidine rinse-off shampoo is authorised for cats. There is no exact-product feline dossier; salt, concentration, vehicle, wash-off versus leave-on use and disease scope differ materially.

Clinical efficacy3.5/10

No exact-product feline outcome trial was found. A rinse-off chlorhexidine/miconazole shampoo label and a small mixed-species study of a different 10% dexpanthenol/decamethoxine ointment offer only indirect class plausibility and cannot establish this leave-on cream’s benefit.

Safety and tolerability3.5/10

The rinse-off feline chlorhexidine label documents external-use, eye, licking and rare local-reaction precautions, but exact leave-on cream tolerance, damaged-skin exposure and grooming ingestion are unknown. Corneal injury and serious hypersensitivity are hard stops, and lanolin/cetyl/stearyl alcohol can cause contact dermatitis.

Clinical practicality4.5/10

Application to a small lesion is simple, but a grooming cat often requires a collar or secure nonconstrictive dressing, repeated handling and close skin checks. Eye/ear/mucosa exclusions and no validated feline amount/frequency materially reduce practicality.

Full-course cost-effectiveness-

A current 30 g Georgian tube price was verified, but lesion-area-adjusted total course use, dressing needs, wastage and comparable veterinary alternatives were not; price is excluded from the denominator.

Important safety and use flags

  • This score covers only adjunctive care of a cleaned small superficial skin wound with credible infection risk. It does not cover deep, puncture/bite, devitalised, heavily contaminated, abscessed, large-area or established infected wounds, pyoderma generally, surgical closure or burns requiring specialist care.
  • Bepanthen Plus is a human medicine and dog/cat use is off-label. No exact-product veterinary amount, frequency or course is established; do not copy the human up-to-four-times-daily label or another chlorhexidine product’s regimen.
  • Examine and clean the wound first. Deep pockets, devitalised tissue, foreign material, bite/puncture injury, exudate, spreading inflammation, fever, pain or poor healing requires drainage, debridement, culture, closure or systemic treatment as clinically indicated.
  • Keep away from eyes and periocular skin, mucosa and the ear canal when tympanic integrity is unknown. Chlorhexidine can cause severe corneal damage; ocular exposure requires immediate copious irrigation and urgent assessment if signs persist.
  • Prevent licking and ingestion until the site is protected or the cream is no longer accessible. Use a collar or secure nonconstrictive dressing when needed, and inspect for maceration, pressure, swelling, discharge or impaired circulation.
  • Stop immediately for increasing erythema, pruritus, pain, swelling, urticaria, facial swelling, breathing difficulty or another local/systemic hypersensitivity sign. Chlorhexidine can rarely cause anaphylaxis; lanolin, cetyl alcohol and stearyl alcohol can cause contact dermatitis.
  • Do not apply over a large area or continue frequent repeated use without review. Exact damaged-skin absorption and repeated-use tolerance are unknown, and canine cell data show concentration-dependent chlorhexidine cytotoxicity even when short healthy-skin exposure appears acceptable.
  • Do not combine on the same site with soaps/anionic compounds or another topical antiseptic without compatibility review. Organic debris can reduce topical antiseptic performance; cleaning and direct lesion contact matter.
  • Do not use antibacterial cream where infection risk is not credible merely to promote healing. Avoid unnecessary antiseptic exposure and choose a non-antiseptic wound/barrier product when that better matches the diagnosed lesion.
  • Safety in pregnant, lactating, breeding or juvenile dogs and cats is not established for repeated use on damaged skin. Make an explicit patient-specific benefit-risk decision and prevent neonate or littermate contact/ingestion.
Assessment sources
  1. Bepanthen Plus GE register2026
  2. Bepanthen Plus Lithuania register2026
  3. Bepanthen Plus HALMED leaflet2024
  4. Bepanthen Plus Aversi 30 g2026
  5. Malaseb dog/cat SPC2025
  6. Mixed-pet dexpanthenol ointment study2023
  7. Topical dexpanthenol review2002
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Dexpanthenol50 mg/g Chlorhexidine5 mg/g
Formulation Type
Cream
Administration route
On the skin
Manufacturer
GP Grenzach Produktions GmbH · Germany
Registration
Georgia Yes, human
In force until 28 Jun 2028
Human (Ministry of Health, RAMA)
№ რ-038463
Verified on: 22 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No exact-product dog/cat amount, frequency or course is established. Potential off-label use is limited to veterinarian-assessed, cleaned, small superficial skin wounds with infection risk. Prevent licking and use a secure nonconstrictive dressing or collar when needed. Do not copy the human up-to-four-times-daily direction or another chlorhexidine product’s regimen.

Glumax, Gel

dexpanthenol 50 mg/g (5%), ophthalmic gel, medical device (human)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Potential supportive ocular-surface lubrication with exact Glumax dexpanthenol 5% + carbomer gel in a dog or cat after diagnosis of dry-eye, exposure-related or epithelial disease
Not rateable
No numerical score assigned
vetman assessment

Glumax

dexpanthenol 50 mg/g (5%), ophthalmic gel, medical device (human)
Assessed clinical scopeDog · Potential supportive ocular-surface lubrication with exact Glumax dexpanthenol 5% + carbomer gel in a dog or cat after diagnosis of dry-eye, exposure-related or epithelial disease · Into the eye
Care settingVeterinarian-directed adjunctive use only after a complete ophthalmic examination and without replacing disease-modifying, anti-infective or surgical care
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Not a medicine · Verified on 22 Oct 2026 Off-label use
Not rateable

A numerical product score cannot responsibly be assigned. Glumax has a verifiable 5% dexpanthenol/carbomer human-device identity and a plausible lubricant rationale, but no exact-product canine dose, ocular PK, repeated-dose tolerance or clinical outcome study was found. Canine studies of other carbomer and lubricant formulations show that vehicles differ in comfort and retention and cannot establish this preserved gel’s efficacy, safety or regimen.

Glumax is correctly treated as a human ophthalmic medical device, not a medicine. Lubrication and dexpanthenol biology are plausible, but indirect human, laboratory and other-formulation evidence does not create an exact-product veterinary score or dose.

Important safety and use flags

  • No exact-product dog/cat efficacy, ocular PK, repeated-dose target-animal safety or dose study was found. Do not convert human, in-vitro or other-lubricant evidence into a veterinary product score.
  • Glumax is a CE-marked human ophthalmic medical device, not a registered medicinal product. Its correct market status is “registration not applicable”; this category does not imply veterinary authorisation or proven veterinary benefit.
  • Use only as supportive lubrication after diagnosis. It is not antibacterial, antiviral, antifungal, anti-inflammatory or tear-stimulating and must not replace condition-specific treatment.
  • Pain, blepharospasm, persistent redness or discharge, corneal opacity/ulceration, trauma or vision change requires prompt complete ophthalmic examination rather than empirical lubricant-only care.
  • The exact multidose gel is preserved with cetrimide, but its concentration and repeated dog/cat tolerance are not established here. Stop and reassess if irritation or ocular-surface worsening occurs; in-vitro cetrimide findings from another formulation are a caution, not proof of Glumax toxicity.
  • Do not copy human use directions or another carbomer, dexpanthenol or lubricant regimen. No diagnosis-independent dog/cat frequency, course or amount is published here.
  • Canine carbomer comparisons and feline peri-anaesthetic lubricant studies used different products and settings. Their comfort, retention and outcome data cannot be assigned to Glumax.
  • Avoid tube-tip contact with the eye, lashes, skin or fingers and do not share a tube between patients. Separate other ophthalmic products by at least 15 minutes unless a veterinary ophthalmologist directs otherwise.
  • The human product information says to use the tube within eight weeks after opening. Follow the exact pack’s storage instructions and discard sooner if contamination, damage or an altered appearance is suspected.
  • Safety in pregnant, lactating, breeding or juvenile dogs and cats is not established. Use only after a patient-specific veterinary benefit-risk decision.
Assessment sources
  1. Glumax exact-product audit2026
  2. ClausMarsh Glumax product page2026
  3. NTC dexpanthenol device portfolio2026
  4. Merck veterinary KCS guidance2026
  5. Canine carbomer-gel comparator2012
  6. Canine lubricant retention2023
  7. Human dexpanthenol postoperative study2003
  8. Human dexpanthenol placebo RCT2009
  9. Human dexpanthenol dry-eye RCT1996
  10. Dexpanthenol 5% ocular-cell study2020
  11. Cetrimide ocular-cell cytotoxicity2008
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Potential supportive ocular-surface lubrication with exact Glumax dexpanthenol 5% + carbomer gel in a dog or cat after diagnosis of dry-eye, exposure-related or epithelial disease
Not rateable
No numerical score assigned
vetman assessment

Glumax

dexpanthenol 50 mg/g (5%), ophthalmic gel, medical device (human)
Assessed clinical scopeCat · Potential supportive ocular-surface lubrication with exact Glumax dexpanthenol 5% + carbomer gel in a dog or cat after diagnosis of dry-eye, exposure-related or epithelial disease · Into the eye
Care settingVeterinarian-directed adjunctive use only after a complete ophthalmic examination and without replacing disease-modifying, anti-infective or surgical care
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Not a medicine · Verified on 22 Oct 2026 Off-label use
Not rateable

A numerical product score cannot responsibly be assigned. Glumax has a verifiable 5% dexpanthenol/carbomer human-device identity and a plausible lubricant rationale, but no exact-product feline dose, ocular PK, repeated-dose tolerance or clinical outcome study was found. Short peri-anaesthetic use of a different feline eye gel and a small heterogeneous feline dry-eye case series cannot establish this preserved gel’s chronic efficacy, safety or regimen.

Glumax is correctly treated as a human ophthalmic medical device, not a medicine. Lubrication and dexpanthenol biology are plausible, but indirect human, laboratory and other-formulation evidence does not create an exact-product veterinary score or dose.

Important safety and use flags

  • No exact-product dog/cat efficacy, ocular PK, repeated-dose target-animal safety or dose study was found. Do not convert human, in-vitro or other-lubricant evidence into a veterinary product score.
  • Glumax is a CE-marked human ophthalmic medical device, not a registered medicinal product. Its correct market status is “registration not applicable”; this category does not imply veterinary authorisation or proven veterinary benefit.
  • Use only as supportive lubrication after diagnosis. It is not antibacterial, antiviral, antifungal, anti-inflammatory or tear-stimulating and must not replace condition-specific treatment.
  • Pain, blepharospasm, persistent redness or discharge, corneal opacity/ulceration, trauma or vision change requires prompt complete ophthalmic examination rather than empirical lubricant-only care.
  • The exact multidose gel is preserved with cetrimide, but its concentration and repeated dog/cat tolerance are not established here. Stop and reassess if irritation or ocular-surface worsening occurs; in-vitro cetrimide findings from another formulation are a caution, not proof of Glumax toxicity.
  • Do not copy human use directions or another carbomer, dexpanthenol or lubricant regimen. No diagnosis-independent dog/cat frequency, course or amount is published here.
  • Canine carbomer comparisons and feline peri-anaesthetic lubricant studies used different products and settings. Their comfort, retention and outcome data cannot be assigned to Glumax.
  • Avoid tube-tip contact with the eye, lashes, skin or fingers and do not share a tube between patients. Separate other ophthalmic products by at least 15 minutes unless a veterinary ophthalmologist directs otherwise.
  • The human product information says to use the tube within eight weeks after opening. Follow the exact pack’s storage instructions and discard sooner if contamination, damage or an altered appearance is suspected.
  • Safety in pregnant, lactating, breeding or juvenile dogs and cats is not established. Use only after a patient-specific veterinary benefit-risk decision.
Assessment sources
  1. Glumax exact-product audit2026
  2. ClausMarsh Glumax product page2026
  3. NTC dexpanthenol device portfolio2026
  4. Merck veterinary KCS guidance2026
  5. Feline peri-anaesthetic lubricant study2015
  6. Feline aqueous tear-deficiency series2019
  7. Human dexpanthenol postoperative study2003
  8. Human dexpanthenol placebo RCT2009
  9. Human dexpanthenol dry-eye RCT1996
  10. Dexpanthenol 5% ocular-cell study2020
  11. Cetrimide ocular-cell cytotoxicity2008
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Dexpanthenol50 mg/g
Formulation Type
Gel
Administration route
Into the eye
Manufacturer
NTC S.r.l. · Italy
Registration
Georgia Not a medicine
Not applicable (not a medicine)
In the register: გლუმაქსი 5% 10გ თვ/გელი
Verified on: 22 Oct 2026
 EU Not a medicine
Not applicable (not a medicine)
Verified on: 15 Oct 2026
 UK Not a medicine
Not applicable (not a medicine)
Verified on: 15 Oct 2026
 US Not a medicine
Not applicable (not a medicine)
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog/cat dose, treatment frequency or veterinary indication is established for this exact product. It is a CE-marked human ophthalmic medical device for lubrication/ocular-surface support, not an authorised veterinary medicine. Do not copy its human instructions or regimens from other carbomer, lubricant or dexpanthenol products.

Ivermek Gel 1/50/15 mg/ml, Gel

30 ml for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full dog label: diagnosed otodectic otitis, demodicosis and sarcoptic or notoedric mange treated with an ivermectin 0.1% gel with lidocaine and dexpanthenol, by ear or on lesions
4.7/10
Weak evidence support
vetman assessment

Ivermek Gel

1/50/15 mg/ml, 30 ml for dogs and cats
Assessed clinical scopeDog · Full dog label: diagnosed otodectic otitis, demodicosis and sarcoptic or notoedric mange treated with an ivermectin 0.1% gel with lidocaine and dexpanthenol, by ear or on lesions · On the skin
Care settingVeterinary-diagnosed mite infection with MDR1 status considered, licking prevented and follow-up skin scrapes or ear cytology
vetman score 4.7/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000935 · Verified on 21 Oct 2026

A weak option: an ivermectin ear and skin gel with plausible ear-mite activity but no product data and a real MDR1 risk. Isoxazolines are the evidence-based choice for mange and demodicosis.

Regulatory and scientific credibility4.0/10

The gel is registered in Georgia (000935, valid to 2027) with a current Russian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence or independent product evidence.

Clinical efficacy4.5/10

Topical ivermectin has some evidence against ear mites, but there is no product study, and current dermatology practice treats demodicosis and sarcoptic mange with systemic isoxazolines rather than a local gel.

Safety and tolerability5.0/10

Skin doses of 0.2-0.3 ml/kg give 0.2-0.3 mg/kg ivermectin and 10-15 mg/kg lidocaine, which matters in MDR1 breeds and if licked; the label gives no breed warning.

Clinical practicality5.5/10

Ear use needs 1-2 treatments and skin use 2-4 treatments at 5-7 day intervals on prepared lesions, with licking prevented.

Full-course cost-effectiveness-

No verified current Georgian price or patient-adjusted course cost was found; foreign prices were not substituted.

Important safety and use flags

  • Avoid in Collies, Shelties, Australian Shepherds and other MDR1 breeds or crosses unless MDR1-normal: licked or absorbed ivermectin can cause ataxia, blindness, coma and death.
  • Do not combine with another macrocyclic lactone or topical insectoacaricide.
  • Prevent licking; watch for mydriasis, ataxia, tremor or depression after treatment of large skin areas.
  • Confirm mites by skin scrape or ear cytology; for generalised demodicosis or sarcoptic mange use a systemic isoxazoline.
  • Clean the ears first and treat both ears even if only one is affected.
Assessment sources
  1. NITA-FARM Ivermek Gel
  2. Georgia NFA register 20262026
  3. ESCCAP ectoparasite guideline2024
  4. AAHA allergic disease guideline2023
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full cat label: diagnosed otodectic otitis, demodicosis and notoedric or sarcoptic mange treated with an ivermectin 0.1% gel with lidocaine and dexpanthenol, by ear or on lesions
4.7/10
Weak evidence support
vetman assessment

Ivermek Gel

1/50/15 mg/ml, 30 ml for dogs and cats
Assessed clinical scopeCat · Full cat label: diagnosed otodectic otitis, demodicosis and notoedric or sarcoptic mange treated with an ivermectin 0.1% gel with lidocaine and dexpanthenol, by ear or on lesions · On the skin
Care settingVeterinary-diagnosed mite infection with treated area kept small, licking prevented and follow-up ear cytology
vetman score 4.7/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000935 · Verified on 21 Oct 2026

A weak option for cats: usable for confirmed ear mites in small amounts, but lidocaine and ivermectin exposure on larger skin areas is a concern. Authorised selamectin or isoxazoline spot-ons are better supported.

Regulatory and scientific credibility4.0/10

The gel is registered in Georgia (000935, valid to 2027) with a current Russian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence or independent product evidence.

Clinical efficacy5.0/10

Topical ivermectin is a recognised ear-mite treatment in cats and notoedric mange responds to macrocyclic lactones, but this gel has no product study.

Safety and tolerability4.5/10

Cats groom treated skin, and 0.2-0.3 ml/kg on lesions gives 10-15 mg/kg lidocaine, to which cats are sensitive, plus ivermectin exposure that is risky in kittens.

Clinical practicality5.5/10

Ear use needs 1-2 treatments and skin use 2-4 treatments at 5-7 day intervals, with licking prevented.

Full-course cost-effectiveness-

No verified current Georgian price or patient-adjusted course cost was found; foreign prices were not substituted.

Important safety and use flags

  • Treat only limited lesion areas: cats are sensitive to lidocaine, and licked gel can cause salivation, tremor, depression or seizures.
  • Do not combine with another macrocyclic lactone or topical insectoacaricide.
  • Use particular caution in kittens and debilitated cats; no minimum age is stated.
  • Confirm mites by ear cytology or skin scrape and treat in-contact cats and dogs.
  • Clean the ears first and treat both ears even if only one is affected.
Assessment sources
  1. NITA-FARM Ivermek Gel
  2. Georgia NFA register 20262026
  3. ESCCAP ectoparasite guideline2024
  4. AAHA allergic disease guideline2023
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Ivermectin1 mg/ml Lidocaine hydrochloride50 mg/ml Dexpanthenol15 mg/ml
Formulation Type
Gel
Administration route
On the skin
Manufacturer
NITA-FARM LLC · Russia
Manufacturer (register)
Nita-farm Ltd, Russia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1488, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 04 Mar 2027
Veterinary (National Food Agency)
In the register: ივერმეკი® - გელი
№ 000935
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗